Bioatla Stock Analysis

BCAB Stock  USD 0.18  0.02  8.45%   
Below is the normalized historical share price chart for Bioatla extending back to December 16, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Bioatla stands at 0.18, as last reported on the 11th of February 2026, with the highest price reaching 0.18 and the lowest price hitting 0.18 during the day.
IPO Date
16th of December 2020
200 Day MA
0.5409
50 Day MA
0.5519
Beta
1.06
 
Covid
 
Interest Hikes
Bioatla holds a debt-to-equity ratio of 0.028. At present, Bioatla's Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 0, whereas Short and Long Term Debt Total is forecasted to decline to about 714.8 K. With a high degree of financial leverage come high-interest payments, which usually reduce Bioatla's Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Bioatla's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Bioatla's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Bioatla Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Bioatla's stakeholders.
For many companies, including Bioatla, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Bioatla, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Bioatla's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
2.681
Enterprise Value Ebitda
0.3052
Price Sales
4.2173
Shares Float
46.2 M
Wall Street Target Price
10
The current year's Sale Purchase Of Stock is expected to grow to about 413 K, whereas Total Stockholder Equity is forecasted to decline to about 15.6 M. . At present, Bioatla's Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 1.90, whereas Price To Sales Ratio is forecasted to decline to 2.23.
Bioatla is undervalued with Real Value of 2.65 and Target Price of 10.0. The main objective of Bioatla stock analysis is to determine its intrinsic value, which is an estimate of what Bioatla is worth, separate from its market price. There are two main types of Bioatla's stock analysis: fundamental analysis and technical analysis.
The Bioatla stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bioatla's ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.

Bioatla Stock Analysis Notes

About 29.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.15. Bioatla had not issued any dividends in recent years. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. For more info on Bioatla please contact Jay Short at 858 558 0708 or go to https://www.bioatla.com.

Bioatla Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bioatla's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioatla or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bioatla generated a negative expected return over the last 90 days
Bioatla has high historical volatility and very poor performance
Bioatla has some characteristics of a very speculative penny stock
Bioatla has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 11 M. Net Loss for the year was (69.78 M) with loss before overhead, payroll, taxes, and interest of (46.73 M).
Bioatla currently holds about 178.12 M in cash with (71.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from news.google.com: Why STMicroelectronics Shares Are Trading Higher Here Are 20 Stocks Moving Premarket - Benzinga

Bioatla Largest EPS Surprises

Earnings surprises can significantly impact Bioatla's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-05-12
2025-03-31-0.2933-0.260.033311 
2025-08-07
2025-06-30-0.26-0.32-0.0623 
2024-05-14
2024-03-31-0.54-0.480.0611 
View All Earnings Estimates

Bioatla Stock Institutional Investors

Shares
Marshall Wace Asset Management Ltd2025-06-30
80.8 K
Susquehanna International Group, Llp2025-06-30
74.8 K
Magnus Financial Group Llc2025-06-30
47.2 K
Mccormack Advisors International2025-06-30
44.3 K
Alpha Cubed Investments Llc2025-06-30
41.1 K
National Asset Management Inc2025-06-30
30 K
Ubs Group Ag2025-06-30
29.6 K
Columbia Advisory Partners Llc2025-06-30
26.1 K
Commonwealth Equity Services Inc2025-06-30
25.3 K
Vanguard Group Inc2025-06-30
1.8 M
Tang Capital Management Llc2025-06-30
1.4 M
Note, although Bioatla's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bioatla Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.17 M.

Bioatla Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.20)(1.26)
Return On Capital Employed(2.24)(2.13)
Return On Assets(1.20)(1.26)
Return On Equity(5.63)(5.34)

Management Efficiency

Bioatla has return on total asset (ROA) of (1.0509) % which means that it has lost $1.0509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1388) %, meaning that it created substantial loss on money invested by shareholders. Bioatla's management efficiency ratios could be used to measure how well Bioatla manages its routine affairs as well as how well it operates its assets and liabilities. As of February 11, 2026, Return On Tangible Assets is expected to decline to -1.26. The current year's Return On Capital Employed is expected to grow to -2.13. At present, Bioatla's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 57.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 0.26  0.25 
Tangible Book Value Per Share 0.26  0.25 
Enterprise Value Over EBITDA 0.24  0.25 
Price Book Value Ratio 1.81  1.90 
Enterprise Value Multiple 0.24  0.25 
Price Fair Value 1.81  1.90 
Enterprise Value-22.4 M-21.3 M
Evaluating the management effectiveness of Bioatla allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Bioatla Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta
1.06
Return On Assets
(1.05)
Return On Equity
(8.14)

Technical Drivers

As of the 11th of February 2026, Bioatla shows the Risk Adjusted Performance of (0.08), standard deviation of 10.37, and Mean Deviation of 7.37. Bioatla technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bioatla Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Bioatla price series with the more recent values given greater weights.

Bioatla Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioatla insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioatla's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioatla insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bioatla Outstanding Bonds

Bioatla issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioatla uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioatla bonds can be classified according to their maturity, which is the date when Bioatla has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Bioatla Predictive Daily Indicators

Bioatla intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bioatla stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bioatla Forecast Models

Bioatla's time-series forecasting models are one of many Bioatla's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioatla's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Bioatla Bond Ratings

Bioatla financial ratings play a critical role in determining how much Bioatla have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Bioatla's borrowing costs.
Piotroski F Score
6
HealthyView
Beneish M Score
(2.84)
Unlikely ManipulatorView

Bioatla Debt to Cash Allocation

As Bioatla follows its natural business cycle, the capital allocation decisions will not magically go away. Bioatla's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Bioatla currently holds 836 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Bioatla has a current ratio of 7.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bioatla's use of debt, we should always consider it together with its cash and equity.

Bioatla Total Assets Over Time

Bioatla Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Bioatla uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Bioatla Debt Ratio

    
  1.74   
It appears most of the Bioatla's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Bioatla's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Bioatla, which in turn will lower the firm's financial flexibility.

Bioatla Corporate Bonds Issued

Most Bioatla bonds can be classified according to their maturity, which is the date when Bioatla has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Bioatla Short Long Term Debt Total

Short Long Term Debt Total

714,780

At present, Bioatla's Short and Long Term Debt Total is projected to decrease significantly based on the last few years of reporting.

About Bioatla Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioatla prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioatla shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bioatla. By using and applying Bioatla Stock analysis, traders can create a robust methodology for identifying Bioatla entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(7.29)(7.66)
Operating Profit Margin(7.73)(8.12)
Net Loss(7.29)(7.66)
Gross Profit Margin 1.05  1.11 

Current Bioatla Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioatla analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioatla analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceConsensus# of Analysts
10.0Strong Buy4Odds
Bioatla current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bioatla analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bioatla stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bioatla, talking to its executives and customers, or listening to Bioatla conference calls.
Bioatla Analyst Advice Details

Bioatla Stock Analysis Indicators

Bioatla stock analysis indicators help investors evaluate how Bioatla stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioatla shares will generate the highest return on investment. By understating and applying Bioatla stock analysis, traders can identify Bioatla position entry and exit signals to maximize returns.
Begin Period Cash Flow111.5 M
Common Stock Shares Outstanding48.6 M
Total Stockholder Equity14.3 M
Property Plant And Equipment Net1.2 M
Cash And Short Term Investments49 M
Cash49 M
Accounts Payable1.9 M
Net Debt-48.2 M
50 Day M A0.5519
Total Current Liabilities14.5 M
Other Operating Expenses84.9 M
Non Current Assets Total1.2 M
Stock Based Compensation8.9 M

Complementary Tools for Bioatla Stock analysis

When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Correlations
Find global opportunities by holding instruments from different markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios